Evelo Biosciences, Inc.
EVLOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$1898
P/E Ratio—
52W High$0.0006
52W Low$0.0001
Evelo Biosciences, Inc. (EVLO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · EVLO · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.08B | $0.07B | $0.06B | $0.04B |
| G&A Expenses | $0.03B | $0.03B | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $0.11B | $0.12B | $0.09B | $0.09B | $0.06B |
| Operating Income | ($0.11B) | ($0.12B) | ($0.09B) | ($0.09B) | ($0.06B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.11B) | ($0.12B) | ($0.09B) | ($0.09B) | ($0.06B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | ($0.00B) |
| Net Income | ($0.11B) | ($0.12B) | ($0.09B) | ($0.09B) | ($0.05B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-26.28 | $-46.18 | $-47.45 | $-53.49 | $-49.25 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.11B) | ($0.12B) | ($0.09B) | ($0.08B) | ($0.06B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Evelo Biosciences, Inc. data
About Evelo Biosciences, Inc. (EVLO) Income Statement
Evelo Biosciences, Inc. (EVLO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, EVLO reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.11B) — a net profit margin of —.
Frequently asked questions
EVLO · 4 questionsEvelo Biosciences, Inc. (EVLO) reported revenue of $0.00B for 2022, down —% year-over-year.
EVLO revenueEVLO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09